

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 6, 2026

Consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)

Company name: SHIMADZU CORPORATION
 Listing: Tokyo Stock Exchange
 Securities code: 7701
 URL: <https://www.shimadzu.co.jp>
 Representative: Yasunori Yamamoto, President and Representative Director
 Inquiries: Hiroshi Ogasawara, General Manager, Finance and Accounting Dept.
 Telephone: +81-75-823-1127
 Scheduled date to commence dividend payments: —
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended June 30, 2026	130,596	10.3	14,264	17.1	18,486	63.3	13,333	68.3
June 30, 2025	118,370	1.2	12,184	11.2	11,323	(17.3)	7,921	(20.7)

Note: Comprehensive income For the three months ended June 30, 2026: ¥21,140 million [190.8%]
 For the three months ended June 30, 2025: ¥7,268 million [(60.5)%]

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Three months ended June 30, 2026	46.14	—
June 30, 2025	27.42	—

Reference: Operating profit before amortization of goodwill
 For the three months ended June 30, 2026: ¥14,638 million [16.8%]
 For the three months ended June 30, 2025: ¥12,537 million [11.9%]
 The Company uses operating profit before amortization of goodwill as an important management indicator.

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
June 30, 2026	730,470	575,162	78.7
March 31, 2026	737,978	565,166	76.6

Reference: Equity
 As of June 30, 2026: ¥575,152 million
 As of March 31, 2026: ¥565,156 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	—	27.00	—	42.00	69.00
Fiscal year ending March 31, 2027	—				
Fiscal year ending March 31, 2027 (Forecast)		27.00	—	43.00	70.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated earnings forecast for the fiscal year ending March 31, 2027 (April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2027	620,000	10.6	80,000	8.5	81,000	(2.1)	59,000	(2.5)	204.19

Note: Revisions to the earnings forecast most recently announced: Yes

* For matters related to the above forecast, please refer to page 7, “(3) Consolidated Outlook” in “1. Operating Results.”

Reference: Operating profit before amortization of goodwill

¥85,000 million [13.1%]

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

Newly included: – companies (–)

Excluded: – companies (–)

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2026	296,070,227 shares
As of March 31, 2026	296,070,227 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2026	7,130,100 shares
As of March 31, 2026	7,130,002 shares

(iii) Average number of shares outstanding during the period

Three months ended June 30, 2026	288,940,165 shares
Three months ended June 30, 2025	288,918,676 shares

* Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit firm: None

* Proper use of earnings forecasts, and other special matters

1. The consolidated earnings forecast for the fiscal year ending March 31, 2027 that was announced on May 12, 2026 has been revised in this document.
2. The above forecast was calculated based on information available on the date this report was released. Actual results may vary from forecast values, due to various factors in the future. For matters related to the above forecast, please refer to page 7, “(3) Consolidated Outlook” in “1. Operating Results.”

Table of Contents**Index**

1. Operating Results.....	2
(1) Overview of Operating Results for the Period	2
(2) Overview of Financial Status for the Period	7
(3) Consolidated Outlook.....	7
2. Quarterly Consolidated Financial Statements and Significant Notes	8
(1) Quarterly Consolidated Balance Sheets	8
(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income.....	10
(3) Notes on Quarterly Consolidated Financial Statements	12
Notes on Segment Information, Etc.	12
Notes on the Event of Significant Fluctuations in Shareholders' Capital.....	14
Notes on Going-Concern Assumptions	14
Notes on Quarterly Consolidated Statement of Cash Flows	14
Notes on Events After the Reporting Period	15
3. Supplemental Information	17

1. Operating Results

(1) Overview of Operating Results for the Period

During the three months ended June 30, 2026, the global economy remained generally resilient, but uncertainty about the future persisted due to economic sluggishness in the Chinese economy and the normalization of geopolitical risks, such as the prolonged conflict in Ukraine and escalating tensions in the Middle East. On the other hand, the semiconductor-related market was buoyant, and there was also active investment in the pharmaceutical market related to research, development, and production of biopharmaceuticals.

Under these circumstances, the Group focused on expanding its core businesses*, which are emphasized in the Medium-Term Management Plan that began in FY2026. Specifically, we deployed liquid chromatograph systems and mass spectrometer systems to meet the research, development, quality control, and labor-saving needs of the pharmaceutical and food markets. We also advanced our recurring business by strengthening our lineup of reagents and consumables and expanding our service business. Additionally, aiming for growth in growing markets, particularly the semiconductor market, we worked on enhancing sales of turbomolecular pumps, the main products of our Industrial Machinery segment, and expanding service bases to grow our recurring business.

Given the above, Shimadzu posted net sales for the three months ended June 30, 2026 of 130,596 million yen (a year-on-year increase of 10.3%), reflecting the positive impact of currency exchange due to the depreciation of the yen, setting a new record high. Operating profit was 14,264 million yen (a year-on-year increase of 17.1%). Ordinary profit was 18,486 million yen (a year-on-year increase of 63.3%), and profit attributable to owners of parent was 13,333 million yen (a year-on-year increase of 68.3%). Operating profit before amortization of goodwill was 14,638 million yen.

*Note: Core business: Liquid chromatograph systems, mass spectrometer systems, gas chromatograph systems, and recurring business

The results for reportable business segments were as follows. For the three months ended June 30, 2026, the Group changed its important management indicator from operating profit to operating profit before amortization of goodwill. Accordingly, segment profit represents operating profit before amortization of goodwill for each segment in the following section.

I. Analytical & Measuring Instruments

In the Analytical & Measuring Instruments segment, we strengthened sales in growth areas such as the clinical testing, government, and university markets in Europe, and the pharmaceutical market in China. We focused on the active launch of new products and the strengthening of solution proposal capabilities. Additionally, by expanding our lineup and building value chain partnerships, we enhanced after-sales services, reagents, and consumables, and worked to expand the recurring business. These efforts led to an increase in liquid chromatograph systems for the pharmaceutical and clinical testing markets in the life science field. By region, although sales in other Asian countries decreased due to sales delays in India caused by the situation in the Middle East, sales increased in Japan, Europe and North America, resulting in an overall increase.

As a result, the Analytical & Measuring Instruments segment posted net sales of 80,300 million yen (a year-on-year increase of 6.0%), supported by the positive impact of foreign exchange rates. Segment profit increased owing to our value-added strategy, but decreased to 7,668 million yen (a year-on-year decrease of 15.2%) due to sales delays caused by the Middle East situation and higher material costs.

Net sales broken down by major regions are indicated below.

		Consolidated Results for Three Months of FY 2025 (millions of yen)	Consolidated Results for Three Months of FY 2026 (millions of yen)	Percent Increase/ Decrease (%)	Overview
	Japan	24,084	25,080	4.1	Sales of liquid chromatograph systems increased for the pharmaceutical market, and testing machines increased for the electronics and machinery sectors.
	Outside Japan	51,704	55,219	6.8	The overseas sales ratio was 68.8%, up 0.6 pt.
Major regions	North America	9,232	10,264	11.2	Sales of liquid chromatograph systems increased for universities.
	Europe	9,291	11,392	22.6	Sales of mass spectrometer systems increased for clinical testing companies, the government sector, and universities.
	China	16,660	17,008	2.1	Sales of liquid chromatograph systems increased for biopharmaceuticals.
	Other Asian countries	12,056	11,285	(6.4)	In India, sales of mass spectrometer systems decreased due to sales delays caused by the situation in the Middle East.

II. Medical Systems

In the Medical Systems segment, we implemented market penetration strategies for distinctive new products that integrate AI and IoT technologies for image analysis. We also pursued initiatives to improve profitability, including enhancing gross profit through value propositions and reducing sales of less profitable products. As a result of these efforts, sales of general radiography systems, X-ray TV systems, and angiography systems all increased. By region, although net sales in Japan decreased due to a reduction in the handling of less profitable products, net sales increased significantly overseas due to the effects of new products.

As a result, the Medical Systems segment posted net sales of 16,907 million yen (a year-on-year increase of 23.5%), and segment profit was 1,114 million yen, compared to a segment loss of 716 million yen in the same period of the previous year, due to increased sales and improved profitability.

Net sales broken down by major regions are indicated below.

		Consolidated Results for Three Months of FY 2025 (millions of yen)	Consolidated Results for Three Months of FY 2026 (millions of yen)	Percent Increase/ Decrease (%)	Overview
	Japan	7,043	6,783	(3.7)	Although sales of X-ray systems, particularly general radiography systems and X-ray TV systems, increased, sales decreased due to a reduction in the handling less profitable products.
	Outside Japan	6,648	10,123	52.3	The overseas sales ratio was 59.9%, up 11.3 pt.
Major regions	North America	2,306	3,263	41.5	Sales of general radiography systems and mobile X-ray systems increased due to the effect of new products.
	Europe	367	988	169.0	Sales of general radiography systems and mobile X-ray systems increased due to the effect of new products.
	China	859	1,397	62.7	Sales of general radiography systems and X-ray TV systems increased by capturing demand from government-promoted economic measures.
	Other Asian countries	1,442	2,077	44.0	In Southeast Asia, a focus area, sales of angiography systems increased.

III. Industrial Machinery

In the Industrial Machinery segment, driven by the expanding demand for advanced semiconductor devices led by generative AI, sales of turbomolecular pumps for semiconductor manufacturing equipment remained strong, and sales in the recurring business also increased. Sales of hydraulic equipment increased, particularly for industrial vehicles and construction machinery. By region, sales increased in all major regions, both in Japan and overseas.

As a result, the Industrial Machinery segment posted net sales of 20,734 million yen (a year-on-year increase of 23.2%), and segment profit was 3,823 million yen (a year-on-year increase of 43.5%) due to the increase in net sales.

Net sales broken down by major regions are indicated below.

		Consolidated Results for Three Months of FY 2025 (millions of yen)	Consolidated Results for Three Months of FY 2026 (millions of yen)	Percent Increase/ Decrease (%)	Overview
	Japan	6,019	7,319	21.6	Sales of turbomolecular pumps for use in semiconductor manufacturing equipment significantly increased, and sales of hydraulic equipment for construction machinery increased.
	Outside Japan	10,813	13,415	24.1	The overseas sales ratio was 64.7%, up 0.5 pt.
Major regions	North America	1,857	2,565	38.1	Sales of turbomolecular pumps for use in semiconductor manufacturing equipment significantly increased.
	Europe	1,034	1,281	23.9	Sales of turbomolecular pumps for use in semiconductor manufacturing equipment significantly increased.
	China	5,671	5,827	2.8	Although sales of turbomolecular pumps for coating equipment decreased, sales of hydraulic equipment for industrial vehicles and agricultural machinery increased.
	Other Asian countries	2,217	3,706	67.1	Sales of turbomolecular pumps for use in semiconductor manufacturing equipment and related services significantly increased in Taiwan and South Korea.

IV. Aircraft Equipment

In the Aircraft Equipment segment, we developed operations by capturing the growing demand for equipment for defense and commercial aircraft. In Japan, sales for the defense field significantly increased due to the government's policy of reinforcing defense capabilities. Overseas, due to the rise in air passenger demand, the commercial aircraft field saw an expansion in demand for aircraft equipment for aircraft manufacturer, as well as an increase in demand for spare parts for airline companies driven by special demand.

As a result, the Aircraft Equipment segment posted net sales of 11,031 million yen (a year-on-year increase of 11.4%), and segment profit of 2,745 million yen (a year-on-year increase of 33.9%) due to the increase in net sales and profitability improvement.

Net sales broken down by major regions are indicated below.

	Consolidated Results for Three Months of FY 2025 (millions of yen)	Consolidated Results for Three Months of FY 2026 (millions of yen)	Percent Increase/ Decrease (%)	Overview
Japan	7,713	8,585	11.3	In the defense field, sales of aircraft equipment increased due to the government's policy of reinforcing defense capabilities.
Outside Japan	2,186	2,446	11.9	The overseas sales ratio was 22.2%, up 0.1 pt.
Major regions North America	1,908	2,019	5.8	Sales increased due to the expanded demand for equipment for commercial aircraft and spare parts for airline companies.

V. Other

Other business segments posted net sales of 1,621 million yen (a year-on-year decrease of 24.8%) and segment profit of 149 million yen (a year-on-year decrease of 37.7%).

(2) Overview of Financial Status for the Period

As of June 30, 2026, while investment securities increased by 13,088 million yen and inventories increased by 7,982 million yen compared to the end of the previous year, notes and accounts receivable - trade, and contract assets decreased by 18,921 million yen and cash and deposits decreased by 13,683 million yen. Consequently, total assets decreased by 7,507 million yen to 730,470 million yen. Liabilities decreased by 17,503 million yen to 155,307 million yen, reflecting decreases of 10,649 million yen in income taxes payable and 8,178 million yen in provision for bonuses. Net assets increased by 9,996 million yen to 575,162 million yen, reflecting increases of 6,565 million yen in valuation difference on available-for-sale securities and 2,148 million yen in retained earnings.

(3) Consolidated Outlook

The future outlook is expected to remain uncertain due to the normalization of geopolitical risks, such as increasing tensions in the Middle East, global monetary policy trends, and other factors impacting the economy. Under this business environment, the Group will continue to actively invest in its core businesses and strive to improve its performance.

Regarding the consolidated earnings forecast, after comprehensively considering the view that the booming semiconductor-related market continues, among other factors, a more limited impact on demand from the Middle East situation than initially anticipated, the continued depreciation of the yen, and the contribution to business performance from the consolidation of Tescan Group a.s. which the Group acquired in July 2026, the Group has decided to upwardly revise the earnings forecast announced on May 12, 2026.

Operating profit before amortization of goodwill is expected to be 85,000 million yen.

(Millions of yen)

	Previous Forecast (A)	Revised Forecast (B)	Increase/ Decrease (B-A)	Percent Increase/ Decrease (%)	(Reference) Results for the Previous Fiscal Year
Net Sales	575,000	620,000	45,000	10.6	560,728
Operating Profit	76,000	80,000	4,000	8.5	73,702
Ordinary Profit	75,000	81,000	6,000	(2.1)	82,753
Profit Attributable to Owners of Parent	55,000	59,000	4,000	(2.5)	60,499

Note: The forecasted results above were calculated based on information available on the date this report was released. Actual results may vary from forecast values, due to various factors in the future.

2. Quarterly Consolidated Financial Statements and Significant Notes

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	167,316	153,632
Notes and accounts receivable - trade, and contract assets	156,326	137,405
Merchandise and finished goods	86,449	90,673
Work in process	29,458	32,352
Raw materials and supplies	36,191	37,055
Other	23,895	28,566
Allowance for doubtful accounts	(1,909)	(1,923)
Total current assets	497,728	477,762
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	56,016	55,726
Machinery, equipment and vehicles, net	12,245	12,247
Land	22,181	22,219
Leased assets, net	1,678	1,654
Construction in progress	2,592	4,231
Other, net	28,100	28,264
Total property, plant and equipment	122,815	124,345
Intangible assets		
Goodwill	7,388	7,230
Other	16,497	16,826
Total intangible assets	23,886	24,056
Investments and other assets		
Investment securities	20,357	33,445
Long-term loans receivable	225	301
Retirement benefit asset	54,422	54,996
Deferred tax assets	10,964	5,858
Other	7,625	9,751
Allowance for doubtful accounts	(48)	(48)
Total investments and other assets	93,546	104,305
Total non-current assets	240,249	252,707
Total assets	737,978	730,470

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	41,532	36,660
Lease liabilities	4,033	3,963
Accounts payable - other	18,905	17,282
Income taxes payable	15,015	4,366
Contract liabilities	41,250	44,827
Provision for bonuses	14,841	6,663
Provision for bonuses for directors (and other officers)	384	92
Provision for share awards	119	40
Provision for recall	772	700
Other	13,392	17,240
Total current liabilities	150,248	131,836
Non-current liabilities		
Lease liabilities	6,450	6,457
Provision for retirement benefits for directors (and other officers)	139	128
Retirement benefit liability	13,810	14,683
Provision for share awards	—	11
Other	2,164	2,189
Total non-current liabilities	22,563	23,470
Total liabilities	172,811	155,307
Net assets		
Shareholders' equity		
Share capital	26,648	26,648
Capital surplus	34,910	34,910
Retained earnings	452,619	454,767
Treasury shares	(26,070)	(26,030)
Total shareholders' equity	488,108	490,297
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	8,163	14,729
Foreign currency translation adjustment	43,402	45,215
Remeasurements of defined benefit plans	25,482	24,911
Total accumulated other comprehensive income	77,048	84,855
Non-controlling interests	9	9
Total net assets	565,166	575,162
Total liabilities and net assets	737,978	730,470

(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income**Quarterly Consolidated Statement of Income**

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Net sales	118,370	130,596
Cost of sales	65,116	70,335
Gross profit	53,253	60,260
Selling, general and administrative expenses	41,069	45,996
Operating profit	12,184	14,264
Non-operating income		
Interest income	339	418
Dividend income	176	265
Insurance claim income	26	25
Subsidy income	40	183
Foreign exchange gains	–	3,378
Other	230	263
Total non-operating income	813	4,534
Non-operating expenses		
Interest expenses	65	59
Donations	15	22
Foreign exchange losses	1,256	–
Share of loss of entities accounted for using equity method	48	65
Other	289	164
Total non-operating expenses	1,674	312
Ordinary profit	11,323	18,486
Extraordinary income		
Gain on sale of non-current assets	6	20
Total extraordinary income	6	20
Extraordinary losses		
Loss on disposal of non-current assets	36	14
Total extraordinary losses	36	14
Profit before income taxes	11,293	18,491
Income taxes - current	1,432	2,766
Income taxes - deferred	1,940	2,391
Total income taxes	3,372	5,158
Profit	7,921	13,332
Loss attributable to non-controlling interests	(0)	(0)
Profit attributable to owners of parent	7,921	13,333

Quarterly Consolidated Statement of Comprehensive Income

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit	7,921	13,332
Other comprehensive income		
Valuation difference on available-for-sale securities	547	6,565
Foreign currency translation adjustment	(877)	1,812
Remeasurements of defined benefit plans, net of tax	(323)	(571)
Total other comprehensive income	(652)	7,807
Comprehensive income	7,268	21,140
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	7,268	21,140
Comprehensive income attributable to non-controlling interests	(0)	0

(3) Notes on Quarterly Consolidated Financial Statements**Notes on Segment Information, Etc.**

1) Segment Information

I From April 1 to June 30 of fiscal year ended March 31, 2026

Information on net sales and profit (loss) by reportable segment

(Millions of yen)

	Reportable segment					Other (Note 1)	Subtotal	Adjust- ments (Note 2)	Total (Note 3)
	Analytical & Measuring Instruments	Medical Systems	Industrial Machinery	Aircraft Equipment	Total for Reportable segment				
Net sales									
Sales to customers	75,789	13,692	16,833	9,899	116,215	2,155	118,370	–	118,370
Inter-segment sales	7	6	6	6	27	561	588	(588)	–
Total	75,797	13,698	16,840	9,906	116,242	2,717	118,959	(588)	118,370
Operating profit (loss)	9,040	(716)	2,664	2,050	13,038	239	13,277	(740)	12,537

- Notes: 1. The “Other” category is a business segment that is not included in the reportable segments. It includes businesses such as real estate rental, real estate management, and construction flooring.
2. An adjustment to segment operating profit (loss) of (740) million yen consists primarily of testing and research expenses and core system-related expenses that are not allocated to the reportable segments.
3. The difference between the total amount of segment operating profit (loss) shown in the table above and the operating profit of 12,184 million yen recorded in the consolidated statement of income is due to a 352 million yen amortization of goodwill, etc. This goodwill, etc., includes intangible assets acquired as identifiable assets on the date of business combination.

II From April 1 to June 30 of fiscal year ending March 31, 2027

1. Information on net sales and profit (loss) by reportable segment

(Millions of yen)

	Reportable segment					Other (Note 1)	Subtotal	Adjust- ments (Note 2)	Total (Note 3)
	Analytical & Measuring Instruments	Medical Systems	Industrial Machinery	Aircraft Equipment	Total for Reportable segment				
Net sales									
Sales to customers	80,300	16,907	20,734	11,031	128,974	1,621	130,596	–	130,596
Inter-segment sales	25	6	20	–	52	610	663	(663)	–
Total	80,325	16,913	20,755	11,031	129,027	2,232	131,259	(663)	130,596
Operating profit	7,668	1,114	3,823	2,745	15,352	149	15,501	(862)	14,638

- Notes:
1. The “Other” category is a business segment that is not included in the reportable segments. It includes businesses such as real estate rental, real estate management, and construction flooring.
 2. An adjustment to segment operating profit of (862) million yen consists primarily of testing and research expenses and core system-related expenses that are not allocated to the reportable segments.
 3. The difference between the total amount of segment operating profit shown in the table above and the operating profit of 14,264 million yen recorded in the consolidated statement of income is due to a 374 million yen amortization of goodwill, etc. This goodwill, etc., includes intangible assets acquired as identifiable assets on the date of business combination.

2. Changes in Reportable Segments

Starting from the period from April 1 to June 30 of fiscal year ending March 31, 2027, the Group has switched from using operating profit to operating profit before amortization of goodwill as an important management indicator, and the method for measuring segment profit has been changed to reflect this change. This change was made to measure the results of continuous earning power in our main business.

The segment information for the period from April 1 to June 30 of fiscal year ending March 31, 2026 has also been adjusted in line with these changes. As a result of these changes, segment operating profit (loss) has increased by 292 million yen in the Analytical & Measuring Instruments segment, 42 million yen in the Medical Systems segment, and 18 million yen in the Industrial Machinery segment, and the total has increased by 352 million yen.

2) Related Information

Information on the Amount of Net Sales by Geographical Segment

From April 1 to June 30 of fiscal year ended March 31, 2026

						(Millions of yen)
Japan	The Americas	Europe	China	Other Asian countries	Other	Total
47,015	18,000	10,884	23,236	15,751	3,482	118,370

From April 1 to June 30 of fiscal year ending March 31, 2027

						(Millions of yen)
Japan	The Americas	Europe	China	Other Asian countries	Other	Total
49,390	21,432	13,989	24,242	17,159	4,381	130,596

Note: Main countries and regions included in the geographical segments other than Japan

The Americas: U.S.A.

Europe: U.K., Germany

China: China

Other Asian countries: India, Southeast Asia, South Korea, Taiwan

Other: Australia, Middle East, Africa

Notes on the Event of Significant Fluctuations in Shareholders' Capital

Not applicable.

Notes on Going-Concern Assumptions

Not applicable.

Notes on Quarterly Consolidated Statement of Cash Flows

The Company has not prepared a quarterly consolidated statement of cash flows for the three months ended June 30, 2026. Amounts of depreciation (including amortization of intangible assets excluding goodwill) and amortization of goodwill are as follows.

			(Millions of yen)
	Three months ended June 30, 2025	Three months ended June 30, 2026	
Depreciation	5,015	5,249	
Amortization of goodwill	212	229	

Notes on Events After the Reporting Period**[Business Combination by Acquisition]**

At the Board of Directors' meeting held on December 25, 2025, the Company resolved to acquire Tescan Group a.s. ("Tescan"), one of the pioneering companies in electron microscopy based in Europe, through a share purchase of all the shares of Glass HoldCo s.r.o., a special purpose company indirectly holding all the shares in Tescan. The Company also concluded a stock transfer agreement on December 25, 2025, and acquired the shares on July 10, 2026.

1. Outline of the business combination**(1) Name of acquired company and its business outline**

Name of the acquired company: Glass HoldCo s.r.o.

Business outline: Administrative services and services of an organizational and economic nature

Name of the acquired company: Tescan Group a.s.

Business outline: Manufacturing and sales of analytical and measuring instruments centered on electron microscopy

(2) Main reason for business combination

Tescan is recognized as one of the pioneering companies in electron microscopy, which is expected to see significant growth within analytical and measurement instruments market. Its products are highly regarded for their robustness and user friendliness, with a proven track record of more than 4,000 units sold across 80 countries worldwide, including regions such as North America, Europe, and Asia, serving applications in materials science, semiconductors, and life sciences. In addition to Scanning Electron Microscopes ("SEM") and Focused Ion Beam SEM ("FIB SEM"), Tescan also handles precision measurement instruments such as Transmission Electron Microscope ("TEM"), and Micro CT systems. The Company believes that Tescan's "surface observation and analysis" capabilities complement the Company's "composition analysis" and "physical property analysis," and will significantly contribute to enhancing the Company's growth potential and profitability.

(3) Date of business combination

July 10, 2026

(4) Legal form of business combination

Share acquisition

(5) Name of company after combination

No change.

(6) Ratio of voting rights acquired

100.0%

(7) Basis for determining the acquirer

It is based on the fact that the Company acquired 100% of voting rights by means of share acquisition in consideration for cash.

2. Acquisition cost of the acquired company and related details of each class of consideration

Consideration for acquisition	Cash	711 million U.S. dollars (115,342 million yen)
	Assumption of the seller's liabilities	40 million U.S. dollars (6,492 million yen)
Acquisition cost		751 million U.S. dollars (121,835 million yen)

The above amounts are the consideration at the time of acquisition. Final amounts may differ from the above due to price adjustments.

3. Major acquisition-related costs
To be determined.

4. Amount of goodwill incurred, reasons for the goodwill incurred, and the method and period of amortization
To be determined.

5. The assets acquired and the liabilities assumed at the acquisition date
To be determined.

[Large Borrowing]

The Company borrowed the following amount on July 1, 2026, for the purpose of allocating funds necessary for the acquisition of shares of Tescan:

- | | |
|-------------------------------------|----------------------------------|
| (1) Lender: | MUFG Bank, Ltd. |
| (2) Aggregate amount of borrowings: | 110,000 million yen |
| (3) Interest rates: | Market interest rate plus spread |
| (4) Drawdown date: | July 1, 2026 |
| (5) Collateral/guarantee: | None |

Refinancing of the borrowings into medium- to long term funds is under consideration.

3. Supplemental Information

Overview of Financial Results for the First Three Months of the Fiscal Year Ending March 2027

Row No.			Consolidated Results for First Three Months of FY 2025	Consolidated Results for First Three Months of FY 2026	Year on Year		FY 2025	FY 2026
			Results	Results	Increase/Decrease	Percent Increase/Decrease	Results	Forecast
1	Net Sales	millions of yen	118,370	130,596	12,225	10.3%	560,728	620,000
2	Net Sales (Analytical & Measuring Instruments)	millions of yen	75,789	80,300	4,510	6.0%	364,908	—
3	Net Sales (Medical Systems)	millions of yen	13,692	16,907	3,215	23.5%	73,794	—
4	Net Sales (Industrial Machinery)	millions of yen	16,833	20,734	3,901	23.2%	71,523	—
5	Net Sales (Aircraft Equipment)	millions of yen	9,899	11,031	1,131	11.4%	43,371	—
6	Net Sales (Other)	millions of yen	2,155	1,621	(533)	(24.8)%	7,130	—
7	Net Sales by Region (Japan)	millions of yen	47,015	49,390	2,374	5.1%	242,581	—
8	Net Sales by Region (Outside Japan)	millions of yen	71,355	81,205	9,850	13.8%	318,147	—
9	Net Sales (The Americas)	millions of yen	18,000	21,432	3,432	19.1%	81,866	—
10	Net Sales (Europe)	millions of yen	10,884	13,989	3,104	28.5%	54,802	—
11	Net Sales (China)	millions of yen	23,236	24,242	1,006	4.3%	91,736	—
12	Net Sales (Other Asian Countries)	millions of yen	15,751	17,159	1,407	8.9%	71,468	—
13	Net Sales (Other)	millions of yen	3,482	4,381	899	25.8%	18,272	—
14	Operating Profit	millions of yen	12,184	14,264	2,079	17.1%	73,702	80,000
15	Operating Profit before Amortization of Goodwill	millions of yen	12,537	14,638	2,101	16.8%	75,142	85,000
16	Ordinary Profit	millions of yen	11,323	18,486	7,162	63.3%	82,753	81,000
17	Profit Attributable to Owners of Parent	millions of yen	7,921	13,333	5,411	68.3%	60,499	59,000
18	Earnings per Share (FY 2026 Q1)	Yen	27.42	46.14	—	—	209.39	204.19
19	Dividend per Share	Yen	—	—	—	—	69.00	70.00
20	Capital Equipment Investment	millions of yen	5,360	7,845	2,485	46.4%	22,117	30,000
21	Depreciation and Amortization	millions of yen	5,015	5,249	233	4.7%	20,381	20,000
22	Total Assets	millions of yen	647,299	730,470	83,170	12.8%	737,978	—
23	Net Assets	millions of yen	493,549	575,162	81,612	16.5%	565,166	—
24	Equity-to-Asset Ratio	%	76.2	78.7	—	—	76.6	—
25	Number of All Group Employees	Employees	14,753	14,885	132	—	14,649	—
26	Number of Consolidated Subsidiaries	Companies	78	75	—	—	77	—

Row No.			Consolidated Results for First Three Months of FY 2025	Consolidated Results for First Three Months of FY 2026	Year on Year		FY 2025	FY 2026
			Results	Results	Increase/Decrease	Percent Increase/ Decrease	Results	Forecast
27	Japan	Companies	21	21	—	—	21	—
28	Outside Japan	Companies	57	54	—	—	56	—